New York State Teachers Retirement System (NYSTRS)’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.6M Buy
191,264
+2,180
+1% +$19.9K ﹤0.01% 1169
2026
Q1
$1.7M Sell
189,084
-7,908
-4% -$125K ﹤0.01% 1110
2025
Q4
$3.59M Sell
196,992
-14,817
-7% -$250K 0.01% 920
2025
Q3
$3.1M Sell
211,809
-10,652
-5% -$183K 0.01% 962
2025
Q2
$4.05M Buy
222,461
+571
+0.3% +$11.6K 0.01% 855
2025
Q1
$4.4M Buy
221,890
+108,800
+96% +$1.88M 0.01% 821
2024
Q4
$1.94M Buy
113,090
+21,976
+24% +$413K ﹤0.01% 1123
2024
Q3
$1.82M Buy
+91,114
New +$1.42M ﹤0.01% 1139

Other funds holding ADMA

New York State Teachers Retirement System (NYSTRS)'s ADMA Position: Q2 2026 in Review

New York State Teachers Retirement System (NYSTRS) increased its ADMA Biologics (ADMA) stake by 1.2% in Q2 2026, buying an estimated $19.9K and bringing the position to 191,264 shares worth $1.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1169.

New York State Teachers Retirement System (NYSTRS) first reported a position in ADMA in Q3 2024 and has held it in 8 quarters since. The position peaked at $4.4M in Q1 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • New York State Teachers Retirement System (NYSTRS) held 191,264 shares of ADMA Biologics worth $1.6M as of Q2 2026.
  • New York State Teachers Retirement System (NYSTRS) bought 2,180 ADMA Biologics shares in Q2 2026, an estimated $19.9K.
  • ADMA Biologics made up ﹤0.01% of New York State Teachers Retirement System (NYSTRS)'s portfolio in Q2 2026, its #1169 holding.
  • New York State Teachers Retirement System (NYSTRS) first reported a position in ADMA Biologics in Q3 2024 and has held it in 8 quarters since.
  • New York State Teachers Retirement System (NYSTRS)'s ADMA Biologics position peaked at $4.4M in Q1 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on New York State Teachers Retirement System (NYSTRS)'s 13F filing for Q2 2026, filed 23 Jul 2026.